FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Greenstein Leonard M.						2. Issuer Name and Ticker or Trading Symbol Tarsus Pharmaceuticals, Inc. [ TARS ]									k all app Direc		ng Per	rson(s) to Is 10% O Other (	wner
(Last) (First) (Middle) C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160						3. Date of Earliest Transaction (Month/Day/Year) 08/18/2022									belov	below)		below)	
(Street) IRVINE CA 92618 (City) (State) (Zip)					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X	· .				
		Table	I - No	n-Deriva	tive S	Secui	rities	Acq	uired	, Dis	posed of	, or E	Benef	icially	/ Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day					Execution Date		Date,	3. Transaction Code (Instr. 8) 4. Securitie Disposed (5)					4 and Secur Benef		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) (D)	or Pr	ice	Transa	action(s) 3 and 4)			(111511.4)
Common Stock 08/18/2					2022				S <sup>(1)</sup>		5,000	D	\$1	16.3(2)	64	64,289(3)		D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		Code ( 8)	Transaction Code (Instr. 8)  Deriva Secur Acqui (A) or Dispoor of (D) (Instr. and 5)		rative rities nired r osed )	6. Date Expirat (Month	h/Day/Y	ear) Securitie Underlyir Derivativ Security 3 and 4)  Ar or Ntt		int of rities rlying ative rity (Ins	De Ser (Instr.	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022.
- 2. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from \$15.99 to \$16.71. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. Includes 862 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022.

## Remarks:

/s/ Leonard M. Greenstein

08/19/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.